-+ 0.00%
-+ 0.00%
-+ 0.00%

ACRIVON ADVANCES ACR-2316, A POTENTIAL FIRST-IN-CLASS WEE1/PKMYT1 INHIBITOR, INTO RANDOMIZED DOSE EXPANSION IN ITS ONGOING PHASE 1/2 STUDY

Reuters·08/05/2026 12:30:02

Please log in to view news